A random forest model predicts responses to infliximab in Crohn’s disease based on clinical and serological parameters-Reference-Cited by-同舟云学术

A random forest model predicts responses to infliximab in Crohn’s disease based on clinical and serological parameters

Published:2021-07-24 Issue:9 Volume:56 Page:1030-1039
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Li Yong¹^ORCID,Pan Jianfeng¹^ORCID,Zhou Nan¹,Fu Dongni¹,Lian Guanghui¹,Yi Jun¹,Peng Yu¹^ORCID,Liu Xiaowei¹²^ORCID

Affiliation:

1. Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, China

2. Hunan International Scientific and Technological Cooperation Base of Artificial Intelligence Computer Aided Diagnosis and Treatment for Digestive Disease, Xiangya Hospital, Central South University, Changsha, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2021.1939411

Reference61 articles.

1. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

2. Real-world Experience of Anti–tumor Necrosis Factor Therapy for Internal Fistulas in Crohnʼs Disease

3. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease

4. Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials

5. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artificial intelligence in the diagnostics and treatment of inflammatory bowel diseases (review);Koloproktologia;2024-09-21

2. CT-based body composition parameters predict the loss of response to infliximab in patients with Crohn's disease;The American Journal of the Medical Sciences;2024-09

3. Machine learning application in autoimmune diseases: State of art and future prospectives;Autoimmunity Reviews;2024-02

4. Artificial intelligence in gastroenterology and hepatology;Artificial Intelligence in Clinical Practice;2024

5. A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease;Annals of Medicine;2023-07-21